Noninferiority trials
Open Access
- 1 April 2000
- journal article
- Published by Springer Nature in Trials
- Vol. 1 (1) , 19-21
- https://doi.org/10.1186/cvm-1-1-019
Abstract
Noninferiority trials are intended to show that the effect of a new treatment is not worse than that of an active control by more than a specified margin. These trials have a number of inherent weaknesses that superiority trials do not: no internal demonstration of assay sensitivity, no single conservative analysis approach, lack of protection from bias by blinding, and difficulty in specifying the noninferiority margin. Noninferiority trials may sometimes be necessary when a placebo group can not be ethically included, but it should be recognized that the results of such trials are not as credible as those from a superiority trial.Keywords
This publication has 9 references indexed in Scilit:
- Design Issues in Noninferiority/Equivalence TrialsDrug Information Journal, 1999
- Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trialThe Lancet, 1999
- Some Issues in the Design and Analysis of Equivalence TrialsDrug Information Journal, 1999
- Equivalence TrialsNew England Journal of Medicine, 1997
- A Comparison of Continuous Infusion of Alteplase with Double-Bolus Administration for Acute Myocardial InfarctionNew England Journal of Medicine, 1997
- A Comparison of Reteplase with Alteplase for Acute Myocardial InfarctionNew England Journal of Medicine, 1997
- Trials to assess equivalence: the importance of rigorous methodsBMJ, 1996
- Intention to treat – who should use ITT?British Journal of Cancer, 1993
- Clinical and statistical issues in therapeutic equivalence trialsEuropean Journal of Clinical Pharmacology, 1993